Kazia Therapeutics to Showcase Novel Nuclear PD-L1 Degrader
Sydney, Australia, November 12, 2026 Kazia Therapeutics Limited, an oncology-focused biotechnology company, has announced that it will host a...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Sydney, Australia, November 12, 2026 Kazia Therapeutics Limited, an oncology-focused biotechnology company, has announced that it will host a...
Peachtree Corners, Georgia, USA, November 10, 2026 IMVIONIX Inc. has acquired the exclusive commercial rights to BEOVU® (brolucizumab-dbll) in...
Phoenixville, Pennsylvania, USA, November 10, 2026 Bechtel Medical, Inc. has received 510(k) clearance from the U.S. Food and Drug...
Shanghai, China, November 11, 2026 Abbisko Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has approved...
St. Louis, Missouri, USA, and Tokyo, Japan, November 10, 2026 C2N Diagnostics has entered a strategic partnership with LSI...
San Mateo, California, USA, November 11, 2026 Helix has launched its Research Access Program, offering selected academic and nonprofit...
San Diego, California, USA, November 12, 2026 Argá Medtech has announced the completion of enrollment in the paroxysmal atrial...
Mumbai, India, November 12, 2026 Lupin Limited has announced the European commercial launch of Ranluspecâ„¢ (ranibizumab), its biosimilar medicine...
Tel Aviv, Israel, and Parsippany, New Jersey, U.S., November 11, 2026 Teva Pharmaceutical Industries Ltd. has unveiled its next...
Framingham, Massachusetts, U.S., November 11, 2026 Alzheon, Inc. has announced significant progress in its Alzheimer’s disease research programme, highlighting...
